Q4 2024 Management View CEO Jennifer Ernst highlighted significant advancements, including the acquisition of exclusive worldwide rights to the Phase III immunomodulatory drug candidate Entolimod, ...
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
The company also reported that its fourth quarter revenues dropped 7 percent from a year ago, while its full-year 2024 revenues declined 3 percent.
The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is ...
Zacks Investment Research on MSN8h
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Typically, healthcare professionals prescribe antibiotics, such as amoxicillin, doxycycline, and cefuroxime axetil, to treat the early stages of Lyme disease.
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback